Iambic Therapeutics (IAM)Director bought ~$11.5M

~$11.5M

Approx. value · 719K sh @ $16.00

2.59M

Holds after · shares reported

Traded

Oct 16, 2026

Filed

Oct 19, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 16, 2026 · this disclosureInsiderDirector purchased ~$11.5M of IAM shares in the open market

What came next

1. Oct 16, 2026Company filing · Form 8-K · Bylaws or charter, Reg FDChanged its bylaws, charter or fiscal year, and shared information with investors

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Iambic Therapeutics

For Iambic Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IAM page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans